Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB

Cancer Cell

Volumn 24, Issue 4, 2013, Pages 423-437

  Kuo, Hsu Ping ^a   Wang, Zhong ^a   Lee, Dung Fang ^b   Iwasaki, Masayuki ^a   Duque Afonso, Jesus ^a   Wong, StephenH K ^a   Lin, Chiou Hong ^a   Figueroa, MariaE ^c   Su, Jie ^b   Lemischka, IhorR ^b   Cleary, MichaelL ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; MIXED LINEAGE LEUKEMIA PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; POLO LIKE KINASE 1; PROTEIN P105; SHORT HAIRPIN RNA; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR HOXA9;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; CLONOGENESIS; COLONY FORMING UNIT GM; CONTROLLED STUDY; DNA METHYLATION; EMBRYONIC STEM CELL; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTONE MODIFICATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LEUKEMIA CELL; LEUKEMOGENESIS; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE MYC; PATHOGENESIS; PHOSPHORYLATION; PRIORITY JOURNAL; PROMOTER REGION; WILD TYPE;

EID: 84885344977     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.08.019     Document Type: Article

References (57)

1. Accordi B., Galla L., Milani G., Curtarello M., Serafin V., Lissandron V., Viola G., te Kronnie G., De Maria R., Petricoin E.F., et al. AMPK inhibition enhances apoptosis in MLL-rearranged pediatric B-acute lymphoblastic leukemia cells. Leukemia 2013, 27:1019-1027.
2. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 2008, 40:499-507.
3. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
4. Birkenkamp K.U., Geugien M., Schepers H., Westra J., Lemmink H.H., Vellenga E. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112.
5. Bitoun E., Oliver P.L., Davies K.E. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 2007, 16:92-106.
6. Cartharius K., Frech K., Grote K., Klocke B., Haltmeier M., Klingenhoff A., Frisch M., Bayerlein M., Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005, 21:2933-2942.
7. Chambers S.M., Boles N.C., Lin K.-Y.K., Tierney M.P., Bowman T.V., Bradfute S.B., Chen A.J., Merchant A.A., Sirin O., Weksberg D.C., et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. Cell Stem Cell 2007, 1:578-591.
8. Chen W., Kumar A.R., Hudson W.A., Li Q., Wu B., Staggs R.A., Lund E.A., Sam T.N., Kersey J.H. Malignant transformation initiated by Mll-AF9: gene dosage and critical target cells. Cancer Cell 2008, 13:432-440.
9. Chen D., Frezza M., Schmitt S., Kanwar J., Dou Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 2011, 11:239-253.
10. Dai Y., Chen S., Wang L., Pei X.-Y., Kramer L.B., Dent P., Grant S. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br. J. Haematol. 2011, 153:222-235.
11. Figueroa M.E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P.J., Schifano E., Booth J., van Putten W., Skrabanek L., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27.
12. Fujinaga K., Irwin D., Huang Y., Taube R., Kurosu T., Peterlin B.M. Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol. Cell. Biol. 2004, 24:787-795.
13. Guenther M.G., Lawton L.N., Rozovskaia T., Frampton G.M., Levine S.S., Volkert T.L., Croce C.M., Nakamura T., Canaani E., Young R.A. Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia. Genes Dev. 2008, 22:3403-3408.
14. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., Jordan C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001, 98:2301-2307.
15. Guzman M.L., Swiderski C.F., Howard D.S., Grimes B.A., Rossi R.M., Szilvassy S.J., Jordan C.T. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl. Acad. Sci. USA 2002, 99:16220-16225.
16. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., Ciceri F., Blaser J.G., Greystoke B.F., Jordan A.M., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21:473-487.
17. Hess J.L., Bittner C.B., Zeisig D.T., Bach C., Fuchs U., Borkhardt A., Frampton J., Slany R.K. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood 2006, 108:297-304.
18. Hideshima T., Ikeda H., Chauhan D., Okawa Y., Raje N., Podar K., Mitsiades C., Munshi N.C., Richardson P.G., Carrasco R.D., Anderson K.C. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114:1046-1052.
19. Hjarnaa P.J., Jonsson E., Latini S., Dhar S., Larsson R., Bramm E., Skov T., Binderup L. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity invitro and invivo. Cancer Res. 1999, 59:5751-5757.
20. Huang B., Yang X.-D., Zhou M.-M., Ozato K., Chen L.-F. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 2009, 29:1375-1387.
21. Jang M.K., Mochizuki K., Zhou M., Jeong H.-S., Brady J.N., Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 2005, 19:523-534.
22. Jiang X.J., Huang K.K., Yang M., Qiao L., Wang Q., Ye J.Y., Zhou H.S., Yi Z.S., Wu F.Q., Wang Z.X., et al. Synergistic effect of panobinostat and bortezomib on chemoresistant acute myelogenous leukemia cells via AKT and NF-κB pathways. Cancer Lett. 2012, 326:135-142.
23. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[κ]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
24. Kim J., Woo A.J., Chu J., Snow J.W., Fujiwara Y., Kim C.G., Cantor A.B., Orkin S.H. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010, 143:313-324.
25. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
26. Krutzik P.O., Nolan G.P. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003, 55:61-70.
27. Lee D.-F., Su J., Ang Y.-S., Carvajal-Vergara X., Mulero-Navarro S., Pereira C.F., Gingold J., Wang H.-L., Zhao R., Sevilla A., et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 2012, 11:179-194.
28. Li C., Wong W.H. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc. Natl. Acad. Sci. USA 2001, 98:31-36.
29. Li C., Chen S., Yue P., Deng X., Lonial S., Khuri F.R., Sun S.Y. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation. J.Biol. Chem. 2010, 285:16096-16104.
30. Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
31. Lin D.C., Zhang Y., Pan Q.J., Yang H., Shi Z.Z., Xie Z.H., Wang B.S., Hao J.J., Zhang T.T., Xu X., et al. PLK1 Is transcriptionally activated by NF-κB during cell detachment and enhances anoikis resistance through inhibiting β-catenin degradation in esophageal squamous cell carcinoma. Clin. Cancer Res. 2011, 17:4285-4295.
32. Liu S., Wu L.C., Pang J., Santhanam R., Schwind S., Wu Y.Z., Hickey C.J., Yu J., Becker H., Maharry K., et al. Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010, 17:333-347.
33. Nakagawa M., Shimabe M., Watanabe-Okochi N., Arai S., Yoshimi A., Shinohara A., Nishimoto N., Kataoka K., Sato T., Kumano K., et al. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors. Blood 2011, 118:6626-6637.
34. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
35. Somervaille T.C.P., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
36. Somervaille T.C.P., Matheny C.J., Spencer G.J., Iwasaki M., Rinn J.L., Witten D.M., Chang H.Y., Shurtleff S.A., Downing J.R., Cleary M.L. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009, 4:129-140.
37. Stam R.W., den Boer M.L., Schneider P., Nollau P., Horstmann M., Beverloo H.B., van der Voort E., Valsecchi M.G., de Lorenzo P., Sallan S.E., et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005, 106:2484-2490.
38. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
39. Takahashi S., Harigae H., Ishii K.K., Inomata M., Fujiwara T., Yokoyama H., Ishizawa K., Kameoka J., Licht J.D., Sasaki T., Kaku M. Over-expression of Flt3 induces NF-kappaB pathway and increases the expression of IL-6. Leuk. Res. 2005, 29:893-899.
40. Tan J., Jones M., Koseki H., Nakayama M., Muntean A.G., Maillard I., Hess J.L. CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis. Cancer Cell 2011, 20:563-575.
41. Thiel A.T., Blessington P., Zou T., Feather D., Wu X., Yan J., Zhang H., Liu Z., Ernst P., Koretzky G.A., Hua X. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
42. Wang Z., Smith K.S., Murphy M., Piloto O., Somervaille T.C.P., Cleary M.L. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 2008, 455:1205-1209.
43. Wang Z., Iwasaki M., Ficara F., Lin C., Matheny C., Wong S.H.K., Smith K.S., Cleary M.L. GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. Cancer Cell 2010, 17:597-608.
44. Wang Q.-F., Wu G., Mi S., He F., Wu J., Dong J., Luo R.T., Mattison R., Kaberlein J.J., Prabhakar S., et al. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome. Blood 2011, 117:6895-6905.
45. Wang X., Zhu K., Li S., Liao Y., Du R., Zhang X., Shu H.-B., Guo A.-Y., Li L., Wu M. MLL1, a H3K4 methyltransferase, regulates the TNFα-stimulated activation of genes downstream of NF-κB. J.Cell Sci. 2012, 125:4058-4066.
46. Wesche H., Gao X., Li X., Kirschning C.J., Stark G.R., Cao Z. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J.Biol. Chem. 1999, 274:19403-19410.
47. Wong P., Iwasaki M., Somervaille T.C.P., So C.W.E., Cleary M.L. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007, 21:2762-2774.
48. Yagi T., Morimoto A., Eguchi M., Hibi S., Sako M., Ishii E., Mizutani S., Imashuku S., Ohki M., Ichikawa H. Identification of a gene expression signature associated with pediatric AML prognosis. Blood 2003, 102:1849-1856.
49. Yamada T., Yamaguchi Y., Inukai N., Okamoto S., Mura T., Handa H. P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol. Cell 2006, 21:227-237.
50. Yeh P.Y., Yeh K.H., Chuang S.E., Song Y.C., Cheng A.L. Suppression of MEK/ERK signaling pathway enhances cisplatin-induced NF-kappaB activation by protein phosphatase 4-mediated NF-kappaB p65 Thr dephosphorylation. J.Biol. Chem. 2004, 279:26143-26148.
51. Yokoyama A., Cleary M.L. Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 2008, 14:36-46.
52. Yokoyama A., Wang Z., Wysocka J., Sanyal M., Aufiero D.J., Kitabayashi I., Herr W., Cleary M.L. Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Mol. Cell. Biol. 2004, 24:5639-5649.
53. Yokoyama A., Somervaille T.C.P., Smith K.S., Rozenblatt-Rosen O., Meyerson M., Cleary M.L. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005, 123:207-218.
54. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
55. Zhang W., Xia X., Reisenauer M.R., Hemenway C.S., Kone B.C. Dot1a-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J.Biol. Chem. 2006, 281:18059-18068.
56. Zuber J., Rappaport A.R., Luo W., Wang E., Chen C., Vaseva A.V., Shi J., Weissmueller S., Fellmann C., Taylor M.J., et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011, 25:1628-1640.
57. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.